Wyeth's Bob Essner - CEO pay
Bob Essner - Wyeth 
Total Compensation: $24.1M
2007 Revenue: $22.4B
2006 Revenue: $20.35B
Change: 10%
Details: Bob Essner's (pictured) 2007 compensation fell to $24.1 million from more than $32 million in 2006, which included $1.7 million in base pay, $10.1 million in stock awards, $4.7 million in options and a $3.2 million bonus. Essner also spent $15,000 on personal use of a company car and driver and $95,000 on air travel. Wyeth's new CEO Bernard Poussot (photo), saw his package decline to $12.7 million from $14.4 million. Poussot took over for outgoing CEO Essner January 1, 2008.
Wyeth News:
Wyeth names Poussot CEO
Wyeth to slash another 1,200 jobs
1,200 Wyeth reps out of work
Wyeth, Pfizer chiefs see pay decline
Comments
By Anonymous | Posted 6:13pm | November 6, 2008
As a "Project Impact" ex-exployee I would think that the executives would forego their bonuses ( all or part) to help save the thousands of jobs that have been "impacted". Is it asking too much for executives to live within their means like the rest of us that struggle daily during these troubled times.
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: